Leerink Partners started coverage on ANI Pharmaceuticals shares.
2 reports, 2 independent
Updated Sep 11
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners started coverage on ANI Pharmaceuticals shares.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Market activity around ANI Pharmaceuticals includes analyst rating issuance and increased buying from Amundi and WINTON GROUP.1 source
Leerink Partners started coverage on ANI Pharmaceuticals shares.1 source
Keep exploring
The entities involved
-
Leerink partners
U.S. investment bank
Related events
- Leerink Partners started coverage on Nautilus Biotechnology on October 6, 2026.
- Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
- Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
- Leerink Partners is acting as a joint book-running manager for an offering by Spyre Therapeutics, Inc.
- Leerink Partners assumed coverage on Nektar Therapeutics shares on October 13, 2026.